These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22028157)

  • 1. Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes.
    Lee SW; Lee S; Kim SH; Kim TH; Kang BS; Yoo SH; Lee MK; Koh WJ; Kang WS; Kim HJ
    Yonsei Med J; 2011 Nov; 52(6):939-47. PubMed ID: 22028157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents.
    Kohnert KD; Augstein P; Zander E; Heinke P; Peterson K; Freyse EJ; Hovorka R; Salzsieder E
    Diabetes Care; 2009 Jun; 32(6):1058-62. PubMed ID: 19244086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes.
    Shim WS; Kim SK; Kim HJ; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
    Eur J Endocrinol; 2006 Oct; 155(4):615-22. PubMed ID: 16990662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with long-term oral hypoglycemic agent responsiveness in korean patients with type 2 diabetes mellitus.
    Kim BY; Jung CH; Mok JO; Kim CH
    Diabetes Metab J; 2011 Jun; 35(3):282-9. PubMed ID: 21785749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of the Meal Tolerance Test in the Care of Patients with Type 2 Diabetes Mellitus.
    Wakasaki H; Shono T; Nakao R; Yamamoto S; Minaga T; Fukuda S; Matsumoto R; Ohoshi T; Naka K; Nanjo K
    Intern Med; 2020; 59(18):2229-2235. PubMed ID: 32938850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of standard test meal in initiation of insulin therapy in type 2 diabetes].
    Koprivica B; Beljić-Zivković T; Ille T
    Srp Arh Celok Lek; 2009; 137(9-10):490-6. PubMed ID: 19950754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum bilirubin concentrations are positively associated with serum C-peptide levels in patients with Type 2 diabetes.
    Chung JO; Cho DH; Chung DJ; Chung MY
    Diabet Med; 2014 Nov; 31(11):1316-22. PubMed ID: 24910105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of β-Cell Function.
    Roy Chowdhury S; Thomas RL; Dunseath GJ; Peter R; Rees DA; North RV; Luzio SD; Owens DR
    J Clin Endocrinol Metab; 2016 Feb; 101(2):572-80. PubMed ID: 26652932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial.
    Weiss SR; Cheng SL; Kourides IA; Gelfand RA; Landschulz WH;
    Arch Intern Med; 2003 Oct; 163(19):2277-82. PubMed ID: 14581245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced.
    Yamamoto Y; Takahara M; Yasuda T; Katakami N; Matsuoka TA; Kaneto H; Shimomura I
    Endocr J; 2014; 61(9):911-9. PubMed ID: 25048394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes.
    Wang XH; Xu F; Cheng M; Wang X; Zhang DM; Zhao LH; Cai HL; Huang HY; Chen T; Zhang XL; Wang XQ; Cheng XB; Su JB; Lu Y
    Endocr J; 2020 Nov; 67(11):1107-1117. PubMed ID: 32684527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function.
    Chen P; Sun Q; Xu L; Li F; Liu H
    Diabetes Res Clin Pract; 2024 Sep; 215():111805. PubMed ID: 39102987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of insulin therapy on non-insulin-dependent diabetics with secondary oral hypoglycemic agent failure.
    Peng YS; Juang JH
    Changgeng Yi Xue Za Zhi; 1998 Sep; 21(3):271-6. PubMed ID: 9849007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes.
    Saisho Y; Kou K; Tanaka K; Abe T; Kurosawa H; Shimada A; Meguro S; Kawai T; Itoh H
    Endocr J; 2011; 58(4):315-22. PubMed ID: 21415555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release.
    Pontiroli AE; Calderara A; Maffi P; Bonisolli L; Carenini A; Piatti PM; Monti LD; Gallus G; Pozza G; Illeni MT
    Diabete Metab; 1989; 15(2):79-84. PubMed ID: 2661281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.